CANbridge Pharmaceuticals Investor Relations Material
Latest events
Study Update
CANbridge Pharmaceuticals
H1 2024
29 Aug, 2024
H2 2023
28 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from CANbridge Pharmaceuticals Inc
Access all reports
CANbridge Pharmaceuticals Inc is a Chinese biopharmaceutical company focused on developing and commercializing treatments for rare diseases and cancer. The company engages in drug discovery, licensing, and clinical development, with a pipeline spanning gene therapy and biologics. It operates in both China and global markets through partnerships and R&D collaborations. The company is headquartered in Beijing, China, and its shares are listed on the HKEX.
)
)
)